Immunogenic dynamics and SARS-CoV-2 variant neutralisation of the heterologous ChAdOx1-S/BNT162b2 vaccination

The CombiVacS study was designed to assess immunogenicity and reactogenicity of the heterologous ChAdOx1-S/BNT162b2 combination, and 14-day results showed a strong immune response. The present secondary analysis addresses the evolution of humoral and cellular response up to day 180. Between April 24...

ver descrição completa

Detalhes bibliográficos
Autores: García-Pérez, Javier|||0000-0003-0300-1810, González-Pérez, María, Castillo de la Osa, María, Borobia, Alberto M.|||0000-0002-8584-3263, Castaño, Luis|||0000-0003-0437-9401, Bertrán, María Jesús, Campins Martí, Magda|||0000-0002-8841-6195, Portolés, Antonio, Lora, David, Bermejo, Mercedes, Conde, Patricia, Hernández-Gutierrez, Lourdes, Carcas, Antonio, Arana-Arri, Eunate|||0000-0001-9759-333X, Tortajada, Marta, Fuentes Camps, Inmaculada|||0000-0003-4993-8422, Ascaso, Ana, García-Morales, María Teresa, Erick de la Torre-Tarazona, Humberto, Arribas, Jose|||0000-0002-7410-9450, Imaz Ayo, Natale|||0000-0001-9087-901X, Mellado-Pau, Eugènia|||0000-0003-3356-2045, Agustí Escasany, M. Antònia|||0000-0003-4594-1122, Pérez-Ingidua, Carla, Gómez de la Cámara, Agustín, Ochando, Jordi, Belda-Iniesta, Cristobal, Frías, Jesús, Alcami, Jose|||0000-0003-0023-7377, Pérez-Olmeda, Mayte
Formato: artículo
Fecha de publicación:2022
País:España
Recursos:Universitat Autònoma de Barcelona
Repositorio:Dipòsit Digital de Documents de la UAB
Idioma:inglés
OAI Identifier:oai:ddd.uab.cat:282460
Acesso em linha:https://ddd.uab.cat/record/282460
https://dx.doi.org/urn:doi:10.1016/j.eclinm.2022.101529
Access Level:acceso abierto
Palavra-chave:Antibodies
Heterologous vaccination
Neutralisation
SARS-CoV-2
Variants
Descrição
Resumo:The CombiVacS study was designed to assess immunogenicity and reactogenicity of the heterologous ChAdOx1-S/BNT162b2 combination, and 14-day results showed a strong immune response. The present secondary analysis addresses the evolution of humoral and cellular response up to day 180. Between April 24 and 30, 2021, 676 adults primed with ChAdOx1-S were enrolled in five hospitals in Spain, and randomised to receive BNT162b2 as second dose (interventional group [IG]) or no vaccine (control group [CG]). Individuals from CG received BNT162b2 as second dose and also on day 28, as planned based on favourable results on day 14. Humoral immunogenicity, measured by immunoassay for SARS-CoV-2 receptor binding domain (RBD), antibody functionality using pseudovirus neutralisation assays for the reference (G614), Alpha, Beta, Delta, and Omicron variants, as well as cellular immune response using interferon-γ and IL-2 immunoassays were assessed at day 28 after BNT162b2 in both groups, at day 90 (planned only in the interventional group) and at day 180 (laboratory data cut-off on Nov 19, 2021). This study was registered with EudraCT (2021-001978-37) and ClinicalTrials.gov (NCT04860739). In this secondary analysis, 664 individuals (441 from IG and 223 from CG) were included. At day 28 post vaccine, geometric mean titres (GMT) of RBD antibodies were 5616·91 BAU/mL (95% CI 5296·49-5956·71) in the IG and 7298·22 BAU/mL (6739·41-7903·37) in the CG (p < 0·0001). RBD antibodies titres decreased at day 180 (1142·0 BAU/mL [1048·69-1243·62] and 1836·4 BAU/mL [1621·62-2079·62] in the IG and CG, respectively; p < 0·0001). Neutralising antibodies also waned from day 28 to day 180 in both the IG (1429·01 [1220·37-1673·33] and 198·72 [161·54-244·47], respectively) and the CG (1503·28 [1210·71-1866·54] and 295·57 [209·84-416·33], respectively). The lowest variant-specific response was observed against Omicron-and Beta variants, with low proportion of individuals exhibiting specific neutralising antibody titres (NT50).

Registos relacionados